Preparation meets amplification.
Evaluate SwiftDNA preparation and target-specific LAMP as connected stages, alongside a route using compatible existing laboratory assays.
PREPARED FOR C-CAMP · AMR INNOVATOR SCHOOL 2026
Breakthrough
by Nature.
From laboratory science to a defined diagnostic product.
We bring a commercial DNA-preparation product, internally investigated LAMP workflows and a developing portable device. We seek C-CAMP’s guidance to turn this foundation into a focused bacterial IVD development plan.
Explore our application9–11 December 2026 · C-CAMP, Bengaluru
APPLICANTPranav ManeeshFull-time Founding Director · Trita Biotech
COMMERCIALLY AVAILABLE
The DNA preparation step.
Approximately 8–10 minutes, without extraction instruments. Prepared DNA still needs a compatible, target-specific downstream assay.
THE OPPORTUNITY
The next breakthrough:
one defined bacterial use.
Our development question is how to connect rapid DNA preparation with a selected bacterial assay in a consistent, testable workflow. Existing Staphylococcus laboratory work provides a starting point for defining the first application.
SwiftDNA XtractDNA preparation · commercially available
SensoAidPortable LAMP pathway · device in development
Why this School, now: align intended use, design requirements, quality records and validation before expanding the product claims.
THE SOLUTION / THE VALUE WE AIM TO BUILD
Connect the steps.
Develop the complete use.
A development proposition to evaluate through a focused IVD programme.
A workflow labs can assess.
Make preparation time, equipment needs, assay compatibility and user requirements explicit. A portable SensoAid route is a further development objective.
Measure the difference.
For the selected application, compare the proposed workflow with an appropriate reference method. Establish performance and practical value from the resulting evidence.
Innovation proposition: bring the preparation, assay and future portable device into one application-led development plan. Comparative advantage and application-specific performance remain to be demonstrated.
01 / OUR PRODUCT-DEVELOPMENT CASE
What goes in.
What each step adds.
Explore the use, preparation, assay and evidence decisions we want to develop through the School.
01 / DEFINE
Start with one bacterial application.
Existing Staphylococcus laboratory work provides a starting point. The first diagnostic application still needs a fixed species, specimen, molecular target and intended user.
- START WITH
- Existing bacterial laboratory records
- WHAT THIS STEP ADDS
- A defined target, sample, user and setting
Why it matters: a clear intended use makes the development and validation work specific.
Choose a numbered step. The explanation stays put while you read.
FROM SAMPLE TO EVIDENCE01 / 04
Bacterial sample
TargetWhich organism or molecular target?SampleWhich specimen or sample type?UseWho tests, and in what setting?
SamplePrepared DNA
8–10 minutes extraction reported · image shows the plant product
Prepared DNASupported lab assay
Compatibility must be verified for the chosen sample and assay.
WHAT THE NEXT EVIDENCE MUST ADDRESS
- PerformanceDetection limits, specificity and interference
- ConsistencyRepeatability, reproducibility and sample compatibility
- Use & qualityWorkflow risks, controls and external evaluation
APPLICATION TO BE DEFINED
Conceptual workflow · no test result is simulated.
02 / SCIENTIFIC FOUNDATION
Work to build on.
Evidence to develop.
Explore the reported work, its scope and the next evidence needed.
50+ experiments
Across development, comparisons and optimisation. This is a programme-wide count, not a clinical cohort.
What this tells us
It shows sustained laboratory development activity. To assess any specific performance claim, reviewers would need its study design, sample numbers, controls and underlying results.
Preparation + LAMP
SwiftDNA and LAMP workflows have been investigated independently and together, with bacterial work including Staphylococcus.
What still needs defining
The exact species, specimen, molecular target and comparator must come from the laboratory records. These observations do not establish compatibility with every sample or downstream assay.
Application validation
The first intended use needs an appropriate analytical, external and clinical evaluation plan before diagnostic performance claims.
What remains unestablished
This brief does not establish final-device clinical accuracy, resistance-marker detection or antibiotic susceptibility testing. The SensoAid device remains in development.
Company-reported development summary. The original gel below is one qualitative example; complete study records and independent verification are not presented here.
A CONCRETE LABORATORY READOUT
SwiftDNA preparation.
Downstream PCR bands.
The original image shared by the team shows a ladder and six sample lanes. The team’s accompanying legend identifies finger-prick blood DNA prepared with SwiftDNA Xtract and amplified with GAPDH primers.
- Lane 1
- 100 bp DNA ladder
- Lanes 2–7
- GAPDH PCR from SwiftDNA-prepared blood DNA
What this supports: a qualitative example of downstream PCR amplification using DNA prepared in this experiment.
How to interpret this evidence
The six sample lanes are not a defined clinical cohort. Independent sample numbers, expected amplicon size, controls, comparator results and repeat-run records are not supplied with this image.
The stated scope of this experiment is blood-derived DNA and GAPDH PCR. This gel does not establish bacterial identification, AMR detection, diagnostic sensitivity/specificity or the performance of the SensoAid device.
NEXT PRODUCT PLAN / COORDINATED PCR WORKFLOW
PLANNED · WORKING NAMESOROU PCR
Complete PCR Workflow Reagent Kit
Sorou (揃う) is Japanese for “to be complete” or “to have all parts of a set present.” The proposed name reflects a kit that connects sample preparation, PCR reagents and gel readout supplies.
Name meaning: Japanese dictionary ↗Planned 20-test configuration, combining Trita’s SwiftDNA preparation with complementary Origin reagents. Select a stage to explore the proposed scope.
01 / SAMPLE PREPARATION
Start with SwiftDNA.
SwiftDNA Xtract forms the extraction stage. The selected sample and downstream assay will determine the compatibility checks for the final kit.
Proposed componentsSwiftDNA extraction reagents, with the sample workflow defined for the selected use.
Development plan, not a launched or clinically validated assay. Standard PCR and gel equipment remain necessary. Final components, assay-specific primers, controls and performance claims require verification.
Why it strengthens this application: the kit is a practical case for learning how to define interfaces, document design inputs, verify component compatibility and build batch-control and quality records.
PUBLICLY DOCUMENTED COLLABORATIONS & ENGAGEMENT
A development team.
Connected to an ecosystem.
Specific relationships, with source links and their scope made clear.
Institute of Advanced Virology
IAV’s official announcement names Trita among eight firms signing R&D MoUs at Kerala’s R&D Summit. The announced framework covers collaborative research, co-development and validation activities.
IAV’s official announcement ↗64 CODON
64 CODON’s gallery documents an MoU exchange with Trita Biotech (Origin Diagnostics). KMTC’s public account describes the collaboration’s aim as sensor-based point-of-care diagnostic development.
Bio Connect 3.0
Bio 360 Life Sciences Park’s public post identifies Dr Maneesh Mailankot, Trita’s CEO, as a contributor to Bio Connect 3.0’s biotechnology and entrepreneurship exchange.
Organiser’s account ↗R&D & REAGENT PARTNER
Origin Diagnostics & Research
Origin’s public company profile describes biotechnology-reagent development and manufacturing since 2013. The planned PCR kit builds on the complementary preparation, amplification and electrophoresis portfolios.
Company profile ↗These records document institutional collaboration and ecosystem participation. They do not establish product-specific endorsement, completed validation, regulatory approval or selection into a funded accelerator.
03 / WHY C-CAMP AMR INNOVATOR SCHOOL 2026
The right learning
at the next development step.
The School’s focus on IVD development, design controls, QMS, GLP, Indian regulation and IP/technology transfer maps directly to our next decisions. Select a priority to see the work we want to take forward.
Our aim is to apply the learning to the bacterial IVD case and the coordinated PCR kit plan, with the scientific and commercial teams working from shared requirements and quality records.
01 / INTENDED USE
One application we can evaluate.
Choose the bacterial target, specimen, intended user and testing setting, grounded in the existing laboratory records.
OUTPUT TO WORK TOWARDSAn intended-use statement with explicit claim boundaries.
FROM THREE DAYS OF LEARNING TO FOLLOW-THROUGH
What we would
take back to Trita.
A proposed 90-day plan to refine with the School’s learning.
- DAYS 01–30 / FOCUS
Define the first use.
Pranav coordinates user requirements with the scientific leads. Review the available records and select the target, specimen, setting and comparator.
- DAYS 31–60 / STRUCTURE
Organise development.
Draft design inputs, workflow risks and verification criteria. Map existing laboratory records against the evidence needed for the intended use.
- DAYS 61–90 / PLAN
Set the next evidence work.
Refine the analytical evaluation plan, quality-document priorities, regulatory questions and IP/technology-transfer actions.
Proposed follow-through objectives; these are planning outputs, with study execution to follow the agreed application and available resources.
04 / THE APPLICANT & SCIENTIFIC TEAM
A full-time applicant.
A team to carry it forward.
Pranav connects customer requirements and product planning with Trita’s scientific leadership.
Pranav
Maneesh
Founding Director · Applicant
Full-time director connecting customer needs, product planning and commercialisation.
LinkedIn ↗Dr Maneesh
Mailankot
CEO & Chief Innovator
Biotechnology and diagnostics entrepreneur with 15+ years of industry experience.
LinkedIn ↗Dr Jayalekshmi
Haripriyan
Promoter & Director
Associate Professor at Amrita, with research in microbial virulence, biofilms and bacteriophage activity against multidrug-resistant bacteria.
LinkedIn ↗RELEVANT ACADEMIC RESEARCH
Dr Jayalekshmi Haripriyan is listed as a co-author of a 2021 mSphere study on an N4-like bacteriophage with activity against multidrug-resistant clinical Pseudomonas aeruginosa isolates. This is scientific background of a promoter, separate from Trita product-validation evidence.
University profile and publication record ↗Why Pranav? As a full-time founding director, his work connects customer needs, procurement, product planning and commercialisation. He would use the School to coordinate a clearer development plan with the scientific leads and R&D partner, Origin Diagnostics & Research.
SUPPORTING MATERIAL / FOR THE REVIEW PANEL
The supporting
application brief.
Download the concise brief, or explore the original gel, source-linked collaborations and planned PCR workflow on this page.
Download the brief info@tritabiotech.com ↗The products
SwiftDNA Xtract
Commercially available rapid DNA preparation, with approximately 8–10 minutes extraction time reported by the company. It does not require extraction instruments. Compatibility must be verified for the selected sample and downstream assay.
SensoAid
A portable molecular-detection pathway based on internally standardised LAMP chemistry. Device engineering and application-specific validation remain in progress.
Explore Trita’s product portfolio ↗The evidence & its limits
The R&D team reports more than 50 in-house experiments, including comparisons and optimisation. This is a programme-wide count, not a clinical sample size. SwiftDNA and LAMP workflows have been investigated independently and together.
Development experience includes Staphylococcus, Candida, Leptospira, Klebsiella and Acinetobacter. These are not a list of validated final-device clinical indications. Internal repeatability and reproducibility observations have been reported; numerical claims require the study design and underlying results.
This summary does not establish clinical accuracy, resistance-marker detection or antibiotic susceptibility testing. A selected original gel is included above; full study datasets and independent verification are not presented.
The C-CAMP development plan
The proposed first application will be defined from existing bacterial laboratory records, including Staphylococcus work. The exact species, specimen, molecular target and reference comparator must be selected before setting performance claims.
- Intended use: define the target, sample, user and setting.
- Design controls: document requirements, workflow risks and verification criteria.
- Validation: plan sensitivity, specificity, interference and reproducibility studies, followed by appropriate external and clinical evaluation.
- Translation: develop QMS/GLP documentation, QC and change control; map Indian regulatory and IP/technology-transfer requirements.
These are next priorities, rather than completed milestones. The School’s learning would support product planning and coordination between Trita’s scientific and commercial teams.
The promoters & directors
Dr Maneesh Mailankot
CEO, Chief Innovator, promoter and director. A biotechnology and diagnostics entrepreneur with more than 15 years of industry experience.
Dr Jayalekshmi Haripriyan
Promoter and director; Associate Professor at Amrita Vishwa Vidyapeetham’s School of Biotechnology, with MSc, MPhil and PhD qualifications. Her academic work includes microbial virulence, quorum sensing and antibiofilm approaches.
Academic profile ↗Pranav Maneesh
Full-time founding director and programme applicant, connecting product development, customer requirements and commercialisation. Responsibilities include marketing, sales, procurement and business planning.
R&D partner: Origin Diagnostics & Research. Academic affiliations describe individual backgrounds and do not imply institutional endorsement.
Visuals, sources & context
The gel is an original image previously shared by the team, reproduced without alteration and with the team-supplied lane legend. The Trita logo, product branding and product visuals come from the company website. SensoAid images are concept illustrations, not evidence of a final validated device. The PlantXtract image shows a plant product, distinct from the bacterial application discussed here.
This non-confidential brief was prepared by Trita for its C-CAMP AMR Innovator School 2026 application. It does not imply programme endorsement.
Trita Biotech website ↗ Trita’s company profile ↗